With 53,000 employees worldwide, Boehringer Ingelheim is a leading global pharmaceutical company that aims to develop novel treatments and technologies. Boehringer Ingelheim invites talented early-career researchers to solve pre-defined scientific questions with innovative solutions for the benefit of patients.
Member of the DDEA Advisory Board, Nicolas Dumoulin, is Head of Corporate Strategy & Development at Boehringer Ingelheim based at the headquarters in Ingelheim, Germany, and encourages members of the DDEA network to file applications.
Visual impairment and blindness have a profound and devastating impact on the lives of the affected person, their families and society. Age-related macular degeneration (AMD) is a leading cause of blindness worldwide, affecting more than 200 million people. In addition, more than 100 million people are affected worldwide by diabetic retinopathies.
The current research question goes like this:
Using innovative cellular systems, how would you propose to explore the multifactorial pathophysiology of retinal diseases with the goal to identify and explore novel therapeutic entry points for patients in need?
– As diabetes is a key driver of several retinal diseases, we welcome applications with innovative solutions from talented early-career researchers within the DDEA network. The models proposed should help to bridge the gap between laboratory research and clinical applications, says Nicolas Dumoulin.
The Postdoc project will be anchored in the Retinopathy team at Boehringer Ingelheim at the Discovery Research site in Biberach/Riss, Germany.
Read more and apply through opn2TALENTS.
Submission deadline: 25 October 2023
Boehringer Ingelheim not only offers funding for postdoctoral researchers. The company has also created the open science portal called opnMe. The aim is to foster scientific collaboration, and, as something unique, Boehringer Ingelheim offers molecules or biologics shipped for free for research.
This makes it a fine match with the strategic initiatives of DDEA, encompassing networking and collaborations across research fields, sectors and borders.
– At Boehringer Ingelheim, we are prepared to share high-quality pharmacological probes coming out of our own research. We want to foster disease biology investigation and research on potential drug candidates. The DDEA is a platform for knowledge sharing and has the network of talented researchers. In my role as member of the DDEA Advisory Board and Head of Strategy & Development at Boehringer Ingelheim, I wish to contribute to bridging the two, says Nicolas Dumoulin.
Visiting Professor David Beran has now finished his white book that compiles existing data on type 1 diabetes in Denmark. Together with the just published article ”Type 1 Diabetes and Health Information Systems: Lessons from Denmark” in the European Medical Journal, the hope is that the white book will be used a...
From understanding carnivorous plants to developing antimicrobial strategies for pen injectors, Sofia Wareham Mathiassen’s research life is characterized by high levels of curiosity and inventiveness. And in many ways, she has only just begun. Sofia Wareham Mathiassen is a biomedical engineer from the Danish ...
Earlier this year saw the establishment of a new research centre focusing on making a difference for people with metabolic disease through RNA medicine. Professor of Medical Biology and member of the DDEA Committee for Education, Louise Torp Dalgaard, will be one of the driving forces behind the new centre. The Cent...
A study found a very high seroprevalence of SARS-CoV-2 antibodies in mother-children pairs in rural north-eastern Tanzania. Line Hjort shares her insights from the study, as well as from her time doing research in Tanzania while the country’s government was downplaying the COVID-19 pandemic. During the first year ...
A proof-of-concept study by DDA-funded Visiting Professor Sam El-Osta’s team demonstrates that ductal cells derived from the human pancreas can be influenced by pharmacological stimulation to regenerate beta-like cells that functionally release insulin. – While pharmaceutical options receive warranted attent...
A Danish Diabetes Academy-funded postdoc project by researcher Rasmus Wibaek and colleagues recently published in Diabetologia gains special attention. The study used data from as far back as 1939 to examine the association between birth weight and risk of type 2 diabetes. For every kilogram added to the birth weigh...
PhD Student and Danish Diabetes Academy grantee Mark P.P. Lyngbæk shares his insights from a study recently published in Nature Metabolism. People with type 2 diabetes benefit greatly from both exercising and dietary weight loss. It may help them reduce or even discontinue their medication. And a little goes a long...
Direct patient involvement in health research can have great advantages. Ph.D. Student Caroline Bruun Abild has first-hand experience from a recent qualitative study on disordered eating in people with type 1 diabetes. People with type 1 diabetes have an increased risk of disordered eating and eating disorders. This...
EAN: 5798 0022 30642
Reference: 1025 0006
CVR: 29 19 09 09
